Rafoxanide

• UNSPSC Description:

  Rafoxanide is a poent, orally active halogenated salicylaniline agent with antiparasitic activity. Rafoxanide interferes with energy metabolism in trematodes by uncoupling oxidative phosphorylation. Rafoxanide is also found to be a potent inhibitor of the BRAF V600E mutant protein, which is important in colorectal cancer. Rafoxanide can be used for the control of infestation with Hemonchus species or Fasciola species in sheep and cattle as well as Oestrus ovis in sheep. Rafoxanide can also be used for cancer research[1][2][3].

• Target Antigen:

  Apoptosis; Oxidative Phosphorylation; p38 MAPK; Parasite; Raf

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;MAPK/ERK Pathway;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/Rafoxanide.html

• Solubility:

  DMSO : ≥ 31 mg/mL

• Smiles:

  O=C(NC1=CC=C(OC2=CC=C(Cl)C=C2)C(Cl)=C1)C3=CC(I)=CC(I)=C3O

• Molecular Weight:

  626.01

• References & Citations:

  [1]El-Banna HA, et, al. Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep. Parasitol Res. 2008 May;102(6):1337-42.|[2]van Wyk JA, et, al. Two field strains of Haemonchus contortus resistant to rafoxanide. Onderstepoort J Vet Res. 1987 Jun;54(2):143-6.|[3]Laudisi F, et al. Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. Cancer Lett. 2019;462:1-11.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  22662-39-1